Status:
ACTIVE_NOT_RECRUITING
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Lead Sponsor:
Liquidia Technologies, Inc.
Collaborating Sponsors:
PPD Development, LP
Conditions:
Pulmonary Arterial Hypertension
Pulmonary Hypertension Due to Lung Diseases
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety...
Detailed Description
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of repeated doses of L606 in patients with PAH or PH-ILD. Cohort A: Subjects with PAH or PH-ILD rec...
Eligibility Criteria
Inclusion
- Key
- Males and females ≥18 and ≤80 years of age.
- Diagnosed with
- PAH belonging to at least 1 of the following subgroups of Group 1 pulmonary hypertension (PH) per European Society of Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH at least 1 year prior to screening. or
- PH-ILD Group 3 European Society of Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH. Subjects with Group 3 PH that is not related to underlying ILD are not eligible.
- Subjects with PAH: Documentation of having PAH as confirmed by RHC meeting the following criteria:
- i. Mean PAP \>20 mmHg. ii. Pulmonary arterial wedge pressure ≤15 mmHg. iii. Pulmonary vascular resistance \>3 Wood units. Subjects with PH-ILD: Confirmation of the underlying ILD must be based on HRCT imaging with demonstration of diffuse parenchymal lung disease and documented by the Investigator or radiology report. Subjects may have any form of ILD or CPFE.
- NYHA functional class II, III, or IV at the screening visit.
- Can complete a screening 6MWD of ≥150 meters
- For subjects with PAH: \>65% of predicted and FEV1/FVC ratio \>65% at screening. For subjects with PH-ILD: \>40% of predicted and FEV1/FVC ratio \>70% at screening.
- Key
Exclusion
- LVEF of ≤45% on a historical echocardiogram.
- History of sleep apnea, or left-sided heart disease (including but not limited to aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, or coronary artery disease) per investigator's discretion.
- Experienced an acute exacerbation of disease or hospitalization for any reason within 30 days of signing the ICF or prior to baseline.
- Musculoskeletal disorder (eg, arthritis affecting the lower limbs, recent hip or knee joint replacement) or any disease that would likely be the primary limit to ambulation or subject is connected to a machine that is not portable enough to allow for a 6MWT.
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2031
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04691154
Start Date
August 1 2021
End Date
March 31 2031
Last Update
December 15 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Pulmonary Specialists
Scottsdale, Arizona, United States, 85258
2
VA Greater Los Angeles Healthcare
Los Angeles, California, United States, 90073
3
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
4
University of South Florida
Tampa, Florida, United States, 33606